Adverse Reactions Of Gemcitabine Combined With Cisplatin In Treating Muscle-invasive Urothelial Carcinoma

ObjectiveTo evaluate the adverse reactions of gemcitabine combined with cispaltin intreating muscle-invasive urothelial carcinoma.MethodsFifty-three patients with muscle-invasive urothelial carcinoma, includingthirty-seven patients with bladder cancer, eight patients with renal pelvis cancer, fourpatients with ureter cancer and four patients with multiple urothelial carcinoma,treated with gemcitabine(800mg/m2) that was dripped intravenously in30minutes onday1, day8and day15, and cisplatin (70mg/m2) that was dripped lucifugal in2hours on day2.The regimen was repeated every28days. Each patient received atleast two cycles. Adverse reactions was evaluated after two cycles.ResultsThe fifty-three patients finished one hundred and fifty-nine cycles. The mainadverse reactions were myelosuppression and gastrointestinal adverse reaction.Different degree myelosuppression appeared in every patient, manifestations of whichincluding decreased white blood cell, blood platelet and hemoglobin. With the ageincreasing, occurrence rate of II~III degree decreased blood platelet and hemoglobinsignificantly increased(P=0.003,P=0.000). Gastrointestinal adverse reaction appearedin thirty-eight patients, manifestations of which including nausea, vomit, poorappetite and constipation. Liver and renal toxicity appeared in twenty-six patients,alopecia in seven patients, rash in three patients. No serious complications wereencountered in all patients.ConclusionAdverse reactions of gemcitabine combined with cisplatin in treating themuscle-invasive urothelial carcinoma is safe and can be tolerated by patients.